Navigation Links
Too Much Sugar on the Menu? A New Tablet Might Someday Block Those Carbs
Date:11/5/2013

MANCHESTER, N.H., Nov. 5, 2013 /PRNewswire/ -- Sugar is everywhere—especially in the packaged and processed foods that have become a staple of today's American diet. Besides sugar, sweeteners lurk on many nutrition labels under the guises of brown rice syrup, fructose, glucose, corn sweetener, maltodextrin and evaporated cane juice, among others. According to the U.S. Department of Agriculture, Americans today eat 43 pounds of caloric sweeteners per year—39 percent more than they did in the 1950s. Consumers should be aware that the absence of sugar on an ingredient list doesn't mean it's not there.

Because sugar consumption has been linked to weight gain and obesity, heart disease, Type 2 diabetes, high blood pressure, depression and mood swings, watching one's sugar intake can be essential to good health. According to the American Heart Association (AHA), common sources of sugar include candy, cookies and ice cream; less obvious sources include condensed milk, canned peaches and cinnamon raisin bagels. The AHA advises that for most men and women, sugar consumption should be capped at 150 and 100 calories per day, respectively. The AHA also advises people to be careful with beverage selection; although soft drinks are an obvious source of sugar, many "better for you" beverages—like sports drinks and fruit drinks—also sneak in sugar. The best thing to do is stick with water.

Given that humans don't always make the best choices, there is another tool being developed that people with diabetes and pre-diabetes—as well as consumers concerned about high blood sugar or carbohydrate intake—should know about. It's called PAZ320 and it's a non-systemic, non-toxic, chewable drug candidate for people with Type 2 diabetes to better manage their blood sugar. The compound, which is currently undergoing testing in clinical trials, is being developed by Boston Therapeutics, Inc., a Manchester, NH pharmaceutical company.

David Platt, an expert in carbohydrate chemistry and CEO of Boston Therapeutics, says, "Everyone needs to make better nutritional choices, but being human, that is not always what happens. That's where PAZ320 might help. Taken before meals, clinical studies show that 45 percent of the study group showed an average 40 percent reduction in blood glucose levels after meals."

If it is approved by the FDA, PAZ320 might one day become an option to consider for people living with diabetes.

For more, visit www.bostonti.com, who paid for the writing and dissemination of this release.

Contact: Laura Radocaj, Dian Griesel Int'l., 212.825.3210


'/>"/>
SOURCE Boston Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Measuring Blood Sugar With Light
2. Severe Low Blood Sugar Occurs Often in Patients With Type 2 Diabetes
3. In Preventing Diabetes-Related Heart Disease, Blood Pressure and Cholesterol Targets are Higher Priorities than Blood Sugar
4. Phase 3 Results Show Canagliflozin as Add-On Therapy to Metformin and Pioglitazone Significantly Lowers Blood Sugar Levels in Adult Patients with Type 2 Diabetes
5. Professor Releases Weight Management and Healthy Blood Sugar Control Products
6. In Pilot Study, a Peptide Controls Blood Sugar in People with Congenital Hyperinsulinism
7. JACO WS-14 Wall Mounted Tablet Security System Announcement
8. ViiV Healthcare announces US regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine for people living with HIV
9. Par Pharmaceutical Begins Shipment of KHEDEZLA (desvenlafaxine) Extended-release Tablets, 50 mg and 100 mg
10. Sanofi US and POZEN Sign Exclusive License Agreement for the Commercialization of PA8140/PA32540 Tablets in the U.S.
11. Mylan Confirms Approval of sANDA for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research and ... Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 Mn ... by 2024, expanding at a CAGR of 5.6% from 2016 ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
(Date:4/19/2017)... April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) ... & Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... , Chief Executive Officer of the Company is scheduled to present ... Richard Bear and the Chairman of the Board, Tony ... ...
Breaking Medicine Technology:
(Date:4/28/2017)... SALT LAKE CITY, UTAH (PRWEB) , ... April ... ... Josée Côté as Account Manager for the North East region. Côté has 20+ ... operations and consulting. Prior to Phytomer, Côté worked with an array of high-end ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor that has ... presence to an educational purpose as the host of the “Informed” series. The program ... a recent episode, the series focuses on thyroid cancer. , Although thyroid cancer is ...
(Date:4/27/2017)... , ... April 27, 2017 , ... ... Insights in Incentives, Rewards, and Recognition: A Nudge Guide," a groundbreaking analysis of ... field. Offering practical takeaways to apply immediately to IRR programs, the report highlights ...
(Date:4/27/2017)... Neb. (PRWEB) , ... April 27, 2017 , ... ... was named the 2017 North American CAREGiverSM of the Year for her extraordinary ... selects one of its 60,000 North American professional caregivers for the prestigious award ...
(Date:4/27/2017)... GA (PRWEB) , ... April 27, 2017 , ... Are ... a tragic spike in water-related accidents and drownings during the summer. While most of ... is that these situations occur every day. Very few people are taking the time ...
Breaking Medicine News(10 mins):